ReviewDiagnostics (Basel, Switzerland)2018
Aneuploid CTC and CEC.
Review in Diagnostics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- Small cell size circulating tumor cells predict the prognosis of high-risk non-muscle invasive bladder cancer patients.Scientific reports · 2025Article
- Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.BMC cancer · 2025Article
- Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features.Endocrine · 2024Article
- Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy.Human cell · 2024Article
- Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients.International urology and nephrology · 2023Article
- The Impact of Surgery on Circulating Malignant Tumour Cells in Oral Squamous Cell Carcinoma.Cancers · 2023Article
- Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer.Frontiers in oncology · 2023Article
- Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas.Cancer science · 2022Article
- Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules.Journal of cancer research and clinical oncology · 2022Article
- [A Rare Case of Extremely High Counts of EpCAMSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022Article
- Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.Molecular cancer · 2022Review
- A Crucial Angiogenesis-Associated Gene MEOX2 Could Be a Promising Biomarker Candidate for Breast Cancer.Frontiers in oncology · 2022Article
- Case report: Post-therapeutic laryngeal carcinoma patient possessing a high ratio of aneuploid CTECs to CTCs rapidly developedFrontiers in oncology · 2022Article
- The Treatment Combining Antiangiogenesis with Chemoradiotherapy Impinges on the Peripheral Circulation Vascular Endothelial Cells and Therapeutic Effect in the Patients with Locally Advanced Nasopharyngeal Carcinoma.BioMed research international · 2022Article
- Comprehensive Atlas of Circulating Rare Cells Detected by SE-iFISH and Image Scanning Platform in Patients With Various Diseases.Frontiers in oncology · 2022Article
- Association of Clinical Features of Colorectal Cancer with Circulating Tumor Cells and Systemic Inflammatory Markers.Disease markers · 2022Article
- SimultaneousAnnals of translational medicine · 2021Article
- Role of aneuploid circulating tumor cells and CD31Molecular oncology · 2021Article
- Identification and Comprehensive Co-Detection of Necrotic and Viable Aneuploid Cancer Cells in Peripheral Blood.Cancers · 2021Article
- Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer.Translational lung cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional circulating tumor cell (CTC) detection technologies are restricted to large tumor cells (> white blood cells (WBCs)), or those unique carcinoma cells with double positive expression of surface epithelial cell adhesion molecule (EpCAM) for isolation, and intracellular structural protein cytokeratins (CKs) for identification. With respect to detecting the full spectrum of highly heterogeneous circulating rare cells (CRCs), including CTCs and circulating endothelial cells (CECs), it is imperative to develop a strategy systematically coordinating all tri-elements of nucleic acids, biomarker proteins, and cellular morphology, to effectively enrich and comprehensively identify CRCs. Accordingly, a novel strategy integrating subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH), independent of cell size variation and free of hypotonic damage as well as anti-EpCAM perturbing, has been demonstrated to enable in situ phenotyping multi-protein expression, karyotyping chromosome aneuploidy, and detecting cytogenetic rearrangements of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.